WHO says it awaits full data from Merck on Covid-19 antiviral pill

12 October 2021 - 11:57 By Stephanie Nebehay
The treatment, molnupiravir, cut the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.
The treatment, molnupiravir, cut the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.
Image: 123RF/LEIGH ANNEF

The World Health Organisation (WHO) is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate Covid-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for US emergency use authorisation.

WHO spokesperson Christian Lindmeier, asked at a UN briefing in Geneva about the drug, said: "Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the Covid-19 pandemic."

The treatment, molnupiravir, cut the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.

Reuters


subscribe